<DOC>
	<DOC>NCT02927795</DOC>
	<brief_summary>This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC. Patients will be enrolled consecutively and will be followed over an observational period of approx. 6 weeks.</brief_summary>
	<brief_title>OTIVACTO Spain Non Interventional Study</brief_title>
	<detailed_description>Purpose: Study Design:</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criteria: 1. Written informed consent prior to participation 2. Female and male patients = or &gt; 40 years of age 3. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and requiring longacting dual bronchodilation (Longacting muscarinic antagonist (LAMA) + Longacting beta2 agonist (LABA)) treatment according to approved Spiolto® Respimat® Summary of Product Characteristics (SmPC) and COPD GOLD guideline recommendation Exclusion criteria: 1. Patients with contraindications according to Spiolto® Respimat® SmPC 2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months 3. Patients continuing Longacting beta2 agonist and inhalative corticosteroids (LABAiCS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of longacting beta2 agonists 4. Patients for whom further followup is not possible at the enrolling site during the planned study period of approx. 6 weeks 5. Pregnancy and lactation 6. Patients currently listed for lung transplantation 7. Current participation in any clinical trial or any other noninterventional study of a drug or device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>